BioPharmSignal logoBioPharmSignal

Biotech News

Trevena Reports Second Quarter 2024 Results and Provides Business Update

Trevena (TRVN)TrevenaEarnings

TRVN (TRVN) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is trvn.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

BCLIBrainstorm Cell Therapeutics Inc.2026-08-14 20:00 EST

BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

CLNNClene Inc.2026-08-14 12:30 EST

Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights

ANVSAnnovis Bio2026-08-14 12:00 EST

Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results

NGENNervGen Pharma2026-08-13 11:30 EST

NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates

RVPHReviva Pharmaceuticals2026-08-12 20:29 EST

Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights

ABOSAcumen Pharmaceuticals2026-08-12 11:00 EST

Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights

ANNXAnnexon, Inc.2026-08-12 10:05 EST

Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

IKTInhibikase Therapeutics2026-08-11 20:01 EST

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity

TSHATaysha Gene Therapies2026-08-11 20:00 EST

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

GANXGain Therapeutics2026-08-11 11:00 EST

Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update

View all latest news

Trevena

Trevena was a specialty neuroscience and pain company focused on opioid-sparing and CNS therapeutics. Its story centered on difficult pain and neurologic indications where commercial uptake depends on both clinical differentiation and regulatory execution.

Recent company news

TRVNTrevena2024-11-07 12:01 EST

Trevena Reports Third Quarter 2024 Results and Provides Business Update

TRVNTrevena2024-10-04 20:05 EST

Trevena Announces Receipt of Nasdaq Delisting Notification

TRVNTrevena2024-08-08 20:05 EST

Trevena Announces Reverse Stock Split

TRVNTrevena2024-08-08 11:00 EST

Trevena Reports Second Quarter 2024 Results and Provides Business Update

TRVNTrevena2024-07-08 13:15 EST

Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty Financing

Stock data

Close
0.00 USD
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States